Ryan Fukushima Sells 20,000 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) COO Ryan Fukushima sold 20,000 shares of the stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $62.50, for a total value of $1,250,000.00. Following the completion of the transaction, the chief operating officer now directly owns 962,442 shares in the company, valued at approximately $60,152,625. This represents a 2.04 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ryan Fukushima also recently made the following trade(s):

• On Tuesday, January 7th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The stock was sold at an average price of $39.61, for a total transaction of $792,200.00.
• On Monday, December 16th, Ryan Fukushima sold 3,500 shares of Tempus AI stock. The shares were sold at an average price of $40.23, for a total transaction of $140,805.00.
• On Wednesday, December 11th, Ryan Fukushima sold 120,000 shares of Tempus AI stock. The stock was sold at an average price of $42.51, for a total transaction of $5,101,200.00.

Tempus AI Stock Up 6.1 %

Shares of TEM traded up $3.97 during mid-day trading on Friday, hitting $68.96. 16,292,734 shares of the company traded hands, compared to its average volume of 12,947,475. The stock has a 50-day moving average price of $44.49 and a two-hundred day moving average price of $49.08. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $79.49. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Loop Capital decreased their price objective on Tempus AI from $57.00 to $52.00 and set a "buy" rating on the stock in a report on Tuesday, January 14th. TD Cowen reaffirmed a "buy" rating and issued a $74.00 price target (up from $58.00) on shares of Tempus AI in a research note on Wednesday. Guggenheim initiated coverage on Tempus AI in a research report on Monday, December 9th. They issued a "buy" rating and a $74.00 price objective for the company. Wolfe Research started coverage on shares of Tempus AI in a report on Friday, December 13th. They issued an "outperform" rating and a $60.00 target price on the stock. Finally, Piper Sandler reaffirmed a "neutral" rating and issued a $70.00 target price (up from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $58.55.

Institutional Investors Weigh In On Tempus AI

Hedge funds have recently added to or reduced their stakes in the stock. First Horizon Advisors Inc. bought a new stake in Tempus AI during the third quarter valued at approximately $30,000. Geode Capital Management LLC grew its position in shares of Tempus AI by 0.4% during the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company's stock valued at $7,537,000 after acquiring an additional 539 shares during the period. FNY Investment Advisers LLC bought a new stake in shares of Tempus AI during the 4th quarter valued at $67,000. IFP Advisors Inc purchased a new stake in shares of Tempus AI in the 4th quarter worth $76,000. Finally, US Bancorp DE bought a new position in Tempus AI in the 4th quarter worth $80,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.